Medical devices, healthcare technology and the business of care
PMA approval · P210006

Thoraflex Hybrid

Vascutek, Ltd. · Decision date Apr 19, 2022

FDA DECISIONP210006

What did the FDA approve?

FDA records P210006 as an original PMA application. The recorded decision is approval, dated Apr 19, 2022.

FDA approval order statement

Approval for the Thoraflex Hybrid. The device is intended for the open surgical repair or replacement of damaged or diseased vessels of the aortic arch and descending aorta with or without involvement of the ascending aorta in cases of aneurysm and/or dissection.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Apr 19, 2022

FDA source record

Regulatory record facts

Identifier
P210006
Regulatory pathway
Premarket approval application
Product code
QSK
Decision code
APPR
Decision date
Apr 19, 2022
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Hybrid stent graft, thoracic aortic lesion treatment.

Product code
QSK
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P210006 received

    Application receipt date recorded by FDA.

  2. P210006 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P210006. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P210006

Product / regulatory recordCompanyPathwayDecision dateSource
Thoraflex HybridP210006/S013
Vascutek, Ltd.PMA supplementJul 30, 2025FDA
Thoraflex HybridP210006/S014
Vascutek, Ltd.PMA supplementOct 16, 2025FDA
Thoraflex HybridP210006/S015
Vascutek, Ltd.PMA supplementOct 29, 2025FDA
Thoraflex HybridP210006/S016
Vascutek, Ltd.PMA supplementJan 29, 2026FDA
Thoraflex HybridP210006/S017
Vascutek, Ltd.PMA supplementApr 20, 2026FDA
Thoraflex HybridP210006/S019
Vascutek, Ltd.PMA supplementJun 24, 2026FDA
Thoraflex HybridP210006/S018
Vascutek, Ltd.PMA supplementSep 8, 2026FDA

Explore the linked device profile

Other records with product code QSK

Product / regulatory recordCompanyPathwayDecision dateSource
Artivion, IncPMA approvalJun 26, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Vascutek, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Newmains Ave., Inchinnan, PA49RR

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records